ABOUT US
MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support. Read more about MC2 Therapeutics.
Platform
We apply our expertise in formulation and clinical practice to ensure treatment satisfaction for the patients and release of the full clinical potential of therapies.
When topical dosage form is considered the right dosage form, our PAD TechnologyTM formulation and drug delivery system offer several unique advantages in the development of potent innovative new topical therapies for immune-mediated and inflammatory conditions. Read more about our platform.
Pipeline
With a holistic focus on patient care, we have developed dermatological skincare products specifically designed to complement medical treatments and provide soothing relief for dry, itchy skin caused by inflammation. Read more about our pipeline.
LATEST NEWS
MC2 Therapeutics Announces Dosing of the first patient in the Wynzora® Phase III Clinical Trial in China
Copenhagen, January 6, 2026 – MC2 Therapeutics, a private pharmaceutical company dedicated to improving the ...
Huadong and MC2 Therapeutics Announce Strategic Collaboration for Biomee® Creams in Greater China
Hangzhou, China and Copenhagen, Denmark, December 31, 2025 – Hangzhou Zhongmei Huadong Pharmaceutical Co ("Huadong"), ...
MC2 Therapeutics Announces License and Commercialization Agreement for Wynzora® Cream in Australia
Copenhagen, January 5, 2026 – MC2 Therapeutics, a private pharmaceutical company dedicated to improving the ...
MC2 Therapeutics Announces Approval of Wynzora® Cream in Canada
MC2 Therapeutics Announces Approval of Wynzora® Cream in Canada
Copenhagen, December 18, 2026 – MC2 Therapeutics, a ...